Holen Sie sich die Stockscreener-App
7.36
1.87%
-0.14
Handel nachbörslich:
7.25
-0.11
-1.49%
Schlusskurs vom Vortag:
$7.50
Offen:
$7.46
24-Stunden-Volumen:
101.69K
Relative Volume:
0.50
Marktkapitalisierung:
$428.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.42M
KGV:
-8.4724
EPS:
-0.8687
Netto-Cashflow:
$-25.01M
1W Leistung:
-7.88%
1M Leistung:
-12.59%
6M Leistung:
+38.48%
1J Leistung:
+77.35%
1-Tages-Spanne:
$7.175
$7.6137
1-Wochen-Bereich:
$7.175
$8.32
52-Wochen-Spanne:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.36 | 436.92M | 0 | -29.42M | -25.01M | -0.8687 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - Investing News Network
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing - TipRanks
Eupraxia testing EoE drug extends cash runway to 2028 - Stock Titan
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - GlobeNewswire Inc.
How the (EPRX.WT.A) price action is used to our Advantage - Stock Traders Daily
(EPRX) Market Insights and Trading Signals (EPRX:CA) - Stock Traders Daily
Canadian Investment Regulatory Organization Trading HaltEPRX.WT - marketscreener.com
Eupraxia Pharmaceuticals stock rating reiterated at Raymond James By Investing.com - Investing.com Canada
(EPRX) Stock Analysis and Trading Signals (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Optimized Trading Opportunities - Stock Traders Daily
Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline - TipRanks
Aug Patterns: Whats the beta of Eupraxia Pharmaceuticals Inc stockGDP Growth & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
(EPRX.WT.A) Trading Strategy and Analysis - Stock Traders Daily
Eupraxia Pharmaceuticals Closes US$63.2 Million Public Offering - Global Legal Chronicle
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
(EPRX) Investment Performance Report (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug - Investing.com Nigeria
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug By Investing.com - Investing.com Australia
(EPRX.WT.A) Technical Pivots with Risk Controls - Stock Traders Daily
EPRXEupraxia Pharmac Latest Stock News & Market Updates - Stock Titan
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Eupraxia Pharmaceuticals closes $63.2M public offering - Investing.com India
Eupraxia Pharmaceuticals closes $63.2M public offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals stock gains after $63M offering - Investing.com Nigeria
Eupraxia Pharmaceuticals stock gains after $63M offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness - TipRanks
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option - marketscreener.com
Eupraxia Pharmaceuticals Closes $63.2 Million Offering - marketscreener.com
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - The Manila Times
Eupraxia Pharmaceuticals Announces Closing of US$63.2 - GlobeNewswire
Long Term Trading Analysis for (EPRX.WT.A) - Stock Traders Daily
Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact - TipRanks
Eupraxia Pharmaceuticals stock falls after pricing $55 million offering By Investing.com - Investing.com Canada
Eupraxia Pharmaceuticals prices $55 million public offering - Investing.com Australia
Eupraxia Pharmaceuticals Prices $55 Million Public Offering - marketscreener.com
Eupraxia Pharmaceuticals stock falls after pricing $55 million offering - Investing.com India
Eupraxia Pharma Prices $55 Mln Offering Of Shares And Warrants; Stock Down - Nasdaq
US Stocks Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2025 Geopolitical Influence & Comprehensive Market Scan Reports - baoquankhu1.vn
Eupraxia Prices $55 Mln Offering To Advance Diffusphere Pipeline - Nasdaq
Eupraxia Pharmaceuticals announces pricing of US $55 million public offering of common shares and pre-funded warrants - marketscreener.com
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline - TipRanks
Eupraxia Pharmaceuticals Announces Pricing Of US $55 Million Public Offering Of Common Shares And Pre-Funded Warrants - TradingView
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):